9051 Mira Mesa Blvd, #910094
San Diego, CA 92191
Tel: 760-390-3989

KRT19 Human

Cytokeratin 19 Human Recombinant
RCP1197

Product Overview

Name	KRT19 Human
Description	
Cytokeratin 19 Human Recombinant	
Accession (Primary)	P08727
Synonyms	
Keratin type I cytoskeletal 19, Cytokeratin-19, CK-19, Keratin-19, K19, KRT19, CK19, K1CS, MGC15366.	
Introduction	
CTK-19 is a member of the keratin family. The keratins are intermediate filament proteins responsible for the structural integrity of epithelial cells and are subdivided into cytokeratins and hair keratins. The type I cytokeratins consist of acidic proteins which are arranged in pairs of heterotypic keratin chains. Unlike its related family members, this smallest known acidic cytokeratin is not paired with a basic cytokeratin in epithelial cells. It is specifically expressed in the periderm, the transiently superficial layer that envelopes the developing epidermis. The type I cytokeratins are clustered in a region of chromosome 17q12-q21.	
Source	
Escherichia Coli.	
Physical Appearance	
Sterile Filtered White lyophilized (freeze-dried) powder.	
Formulation	
The protein (1mg/ml) was lyophilized after from a sterile solution containing 30mM Tris-HCl pH-8, 9.5M urea, 2mM DTT, 2mM EDTA and 10mM methylammonium chloride.	
Stability	
Lyophilized KRT19 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution KRT19 should be stored at 4°C between 2-7 days and for future use below -18°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please prevent freeze-thaw cycles.	
Purity	
Greater than 95.0% as determined by SDS-PAGE.	
Solubility	
It is recommended to reconstitute the lyophilized KRT19 in sterile 18MΩ-cm H2O not less than 100 µg/ml, which can	

9051 Mira Mesa Blvd, #910094
San Diego, CA 92191
Tel: 760-390-3989

then be further diluted to other aqueous solutions.

Reconstitution to filaments

Performed by mixing equimolar amounts of cytokeratins of type I and type II at concentrations of approx. 0.5 mg/ml, both dissolved in 9.5 M urea buffer (see above). Protofilaments and filament complexes are obtained by dialyzing the resulting polypeptide solution stepwise to a concentration of 4 M urea and then to low salt condition (50 mM NaCl, 2 mM dithiothreitol, 10 mM Tris-HCl, pH 7.4). For immunization purposes, the solution can be further dialyzed against PBS (phosphate buffered saline, e.g. Dulbecco's PBS).

Precautions

KRT19 Human is for research use only and not for use in diagnostic or therapeutic procedures.

Target Information: (P08727)